Silo Pharma Inc Cash Flow Conversion Efficiency
Silo Pharma Inc cash flow conversion efficiency. Based on the latest financial reports, Silo Pharma Inc (SILO) has a cash flow conversion efficiency ratio of -0.160x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-781.86K) by net assets ($4.89 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Silo Pharma Inc (2011–2025)
Cash flow conversion efficiency of Silo Pharma Inc from 2011 to 2025. This chart illustrates how Silo Pharma Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View today's stock price for Silo Pharma Inc for real-time trading data and today's change.
Silo Pharma Inc Cash Flow Conversion Ratio Explained
Silo Pharma Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Silo Pharma Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Silo Pharma Inc ranked by their cash flow conversion efficiency. Also see Silo Pharma Inc (SILO) total market value for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Chanson International Holding Class A Ordinary Shares
NASDAQ:CHSN
|
0.073x |
|
Klondike Silver Corp
V:KS
|
0.001x |
|
Lasa Supergenerics Limited
NSE:LASA
|
0.005x |
|
Roman DBDR Acquisition Corp. II Warrants
NASDAQ:DRDBW
|
N/A |
|
AIS Resources Ltd
V:AIS
|
-0.177x |
|
Locafy Ltd
NASDAQ:LCFY
|
-0.083x |
|
TRU PRECIOUS METALS CORP.
F:706
|
0.054x |
|
Superior Industries International
NYSE:SUP
|
0.139x |
Annual Cash Flow Conversion Efficiency for Silo Pharma Inc (2011–2025)
The table below shows the annual cash flow conversion efficiency of Silo Pharma Inc from 2011 to 2025. Review SILO free cash flow to operating cash ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $6.31 Million | $-4.66 Million | -0.739x | +2.93% |
| 2024-12-31 | $5.03 Million | $-3.83 Million | -0.762x | -45.89% |
| 2023-12-31 | $6.18 Million | $-3.22 Million | -0.522x | -54.34% |
| 2022-12-31 | $10.34 Million | $-3.50 Million | -0.338x | -34.55% |
| 2021-12-31 | $9.06 Million | $-2.28 Million | -0.251x | +72.18% |
| 2020-12-31 | $1.28 Million | $-1.16 Million | -0.903x | -102.60% |
| 2019-12-31 | $-22.89K | $-794.32K | 34.699x | +5085.55% |
| 2018-12-31 | $407.44K | $272.64K | 0.669x | +382.84% |
| 2017-12-31 | $1.20 Million | $-284.62K | -0.237x | -39.51% |
| 2016-12-31 | $846.51K | $-143.56K | -0.170x | +67.32% |
| 2015-12-31 | $1.96 Million | $-1.02 Million | -0.519x | -15.64% |
| 2014-12-31 | $2.37 Million | $-1.06 Million | -0.449x | -341.92% |
| 2013-12-31 | $1.79 Million | $-181.61K | -0.102x | -119.48% |
| 2012-12-31 | $-41.19K | $-21.47K | 0.521x | -98.03% |
| 2011-12-31 | $-1.75K | $-46.30K | 26.489x | -- |
About Silo Pharma Inc
Silo Pharma, Inc. operates as a developmental stage biopharmaceutical company. The company is developing therapeutics that address underserved conditions, including post-traumatic stress disorder (PTSD), stress-induced anxiety disorders, fibromyalgia, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in formulations. The company's… Read more